Soft tissue sarcoma

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 6, 2010, Pages 630-674

  Demetri, George D ^a   Antonia, Scott ^a   Benjamin, Robert S ^a   Bui, Marilyn M ^a   Casper, Ephraim S ^a   Conrad III, Ernest U ^a   DeLaney, Thomas F ^a   Ganjoo, Kristen N ^a   Heslin, Martin J ^a   Hutchinson, Raymond J ^a   Kane III, John M ^a   Letson, G Douglas ^a   McGarry, Sean V ^a   O'Donnell, Richard J ^a   Paz, I Benjamin ^a   Pfeifer, John D ^a   Pollock, Raphael E ^a   Randall, R Lor ^a   Riedel, Richard F ^a   Schupak, Karen D ^a   Schwartz, Herbert S ^a   Thornton, Katherine ^a   Von Mehren, Margaret ^a   Wayne, Jeffrey ^a   more..

^a NONE

Author keywords

Chemotherapy; Desmoid tumor; Gastrointestinal stromal tumors; NCCN clinical practice guidelines; NCCN guidelines; Radiation therapy; Retroperitoneal sarcomas; Soft tissue extremity sarcoma; Soft tissue sarcoma; Surgery

Indexed keywords

BEVACIZUMAB; CELECOXIB; CETUXIMAB; CISPLATIN; DACARBAZINE; DASATINIB; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; INTERFERON; MESNA; METHOTREXATE; NAVELBINE; NILOTINIB; PACLITAXEL; PLACEBO; RAPAMYCIN; SORAFENIB; SULINDAC; SUNITINIB; TAMOXIFEN; TEMOZOLOMIDE; TOREMIFENE; VINBLASTINE;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ALVEOLAR SOFT PART SARCOMA; ANEMIA; ANGIOMYOLIPOMA; ANGIOSARCOMA; ANOREXIA; ARTIFICIAL EMBOLISM; ASPIRATION BIOPSY; BLOOD CELL COUNT; BONE METASTASIS; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHORDOMA; CLINICAL OBSERVATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CRYOTHERAPY; DESMOID TUMOR; DIARRHEA; DISEASE FREE SURVIVAL; DISSEMINATED CANCER; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; EVENING DOSAGE; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GIANT CELL TUMOR; HAND FOOR SKIN REACTION; HAND FOOT SKIN REACTION; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEMANGIOPERICYTOMA; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; LAPAROSCOPIC SURGERY; LIVER FUNCTION TEST; LOW DRUG DOSE; LUNG TOXICITY; LYMPHANGIOLEIOMYOMATOSIS; MEDICAL DECISION MAKING; METASTASIS; MORNING DOSAGE; MUCOSA INFLAMMATION; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERIVASCULAR EPITHELIOID CELL TUMOR; PIGMENTED VILLONODULAR SYNOVITIS; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE TREATMENT; RADIOFREQUENCY ABLATION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; SKIN MANIFESTATION; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; STEREOTACTIC RADIOSURGERY; TENOSYNOVIAL GIANT CELL TUMOR; TUMOR BIOPSY; ARTICLE; SARCOMA;

HUMANS; SARCOMA;

EID: 77954166640     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0049     Document Type: Review

References (154)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. D'Amato G, Steinert DM, McAuliffe JC, Trent JC. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 2005;12:44-56.
3. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33:459-465. (Pubitemid 34747864)
4. Zahm S, Fraumeni JJ. The epidemiology of soft tissue sarcoma. Semin Oncol 1997;24:504-514.
5. Coindre J, Terrier P, Guillou L, et al. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001;91:1914-1926.
6. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004;54:94-109.
7. Domanski HA. Fine-needle aspiration cytology of soft tissue lesions: diagnostic challenges. Diagn Cytopathol 2007;35:768-773.
8. Antonescu CR. The role of genetic testing in soft tissue sarcoma. Histopathology 2006;48:13-21.
9. Pfeifer JD, Hill DA, O'Sullivan MJ, Dehner LP. Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics? Histopathology 2000;37:485-500.
10. Hill DA, O'Sullivan MJ, Zhu X, et al. Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a prospective study. Am J Surg Pathol 2002;26:965-977. (Pubitemid 34810557)
11. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar thabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 2002;20:2672-2679.
12. Guillou L, Benhattar J, Bonichon F, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol 2004;22:4040-4050.
13. Ladanyi M, Antonescu CR, Leung DH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 2002;62:135-140.
14. Antonescu CR, Tschernyavsky SJ, Decuseara R, et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 2001;7:3977-3987.
15. Guillou L, Coindre J, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997;15:350-362.
16. Dileo P, Demetri GD. Update on new diagnostic and therapeutic approaches for sarcomas. Clin Adv Hematol Oncol 2005;3:781-791. (Pubitemid 41782641)
17. Mocellin S, Rossi C, Brandes A, Nitti D. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev 2006;32:9-27. (Pubitemid 43159774)
18. Brennan MF, Casper ES, Harrison LB, et al. The role of multimodality therapy in soft-tissue sarcoma. Ann Surg 1991;214:328-336.
19. Kim B, Chen YL, Kirsch DG, et al. An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Oncol Biol Phys 2010; in press.
20. Fleming JB, Berman RS, Cheng SC, et al. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol 1999;17:2772-2780.
21. Gerrand CH, Wunder JS, Kandel RA, et al. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br 2001;83:1149-1155.
22. Pisters PW, Leung DH, Woodruff J, et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996;14:1679-1689. (Pubitemid 26134227)
23. Lewis JJ, Leung D, Espat J, et al. Effect of reresection in extremity soft tissue sarcoma. Ann Surg 2000;231:655-663. (Pubitemid 30249826)
24. Zagars GK, Ballo MT, Pisters PW, et al. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer 2003;97:2544-2553.
25. Ghert MA, Abudu A, Driver N, et al. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol 2005;12:10-17.
26. Stojadinovic A, Jaques DP, Leung DH, et al. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. Ann Surg Oncol 2001;8:509-518. (Pubitemid 32642607)
27. Williard WC, Hajdu SI, Casper ES, Brennan MF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg 1992;215:269-275.
28. DeLaney TF, Trofimov AV, Engelsman M, Suit HD. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control 2005;12:27-35.
29. Leibel SA, Fuks Z, Zelefsky MJ, et al. Intensity-modulated radiotherapy. Cancer J 2002;8:164-176.
30. Davis A, O'Sullivan B, Bell R, et al. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol 2002;20:4472-4477.
31. Sadoski C, Suit H, Rosenberg A, et al. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol 1993;52:223-230. (Pubitemid 23121936)
32. Alektiar KM, Velasco J, Zelefsky MJ, et al. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys 2000;48:1051-1058.
33. Cahlon O, Spierer M, Brennan MF, et al. Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy. Cancer 2008;112:2774-2779. (Pubitemid 351969223)
34. Alektiar KM, Leung D, Zelefsky MJ, et al. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann Surg Oncol 2002;9:48-56. (Pubitemid 34262897)
35. Tran QN, Kim AC, Gottschalk AR, et al. Clinical outcomes of intraoperative radiation therapy for extremity sarcomas. Sarcoma 2006;2006:91671.
36. Clark MA, Thomas JM. Amputation for soft-tissue sarcoma. Lancet Oncol 2003;4:335-342.
37. Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982;196:305-315.
38. Baldini EH, Goldberg J, Jenner C, et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999;17:3252-3259. (Pubitemid 29470660)
39. Lin PP, Guzel VB, Pisters PW, et al. Surgical management of soft tissue sarcomas of the hand and foot. Cancer 2002;95:852-861. (Pubitemid 34839678)
40. O'Sullivan B, Davis A, Turcotte R, et al. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma [abstract]. J Clin Oncol 2004;22(Suppl 1):Abstract 9007.
41. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998;16:197-203.
42. Wilson AN, Davis A, Bell RS, et al. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer 1994;30A:746-751.
43. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996;14:859-868.
44. Alektiar KM, Brennan MF, Healey JH, Singer S. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol 2008;26:3440-3444.
45. Kepka L, DeLaney TF, Suit HD, Goldberg SI. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2005;63:852-859.
46. Clasby R, Tilling K, Smith MA, Fletcher CD. Variable management of soft tissue sarcoma: regional audit with implications for specialist care. Br J Surg 1997;84:1692-1696.
47. Demas BE, Heelan RT, Lane J, et al. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol 1988;150:615-620.
48. Hanna SL, Fletcher BD. MR imaging of malignant soft-tissue tumors. Magn Reson Imaging Clin N Am 1995;3:629-650.
49. Heslin MJ, Smith JK. Imaging of soft tissue sarcomas. Surg Oncol Clin N Am 1999;8:91-107.
50. Schwab JH, Boland P, Guo T, et al. Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread. Ann Surg Oncol 2007;14:1507-1514.
51. Schwab JH, Boland PJ, Antonescu C, et al. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer 2007;110:1815-1822. (Pubitemid 47557307)
52. Tateishi U, Hasegawa T, Beppu Y, et al. Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. AJR Am J Roentgenol 2004;182:725-731.
53. Portera CA Jr, Ho V, Patel SR, et al. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 2001;91:585-591.
54. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol 2006;18:369-373.
55. Folpe AL, Lyles RH, Sprouse JT, et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res 2000;6:1279-1287.
56. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005;103:339-348.
57. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29:1149-1154.
58. Geer RJ, Woodruff J, Casper ES, Brennan MF. Management of small soft-tissue sarcoma of the extremity in adults. Arch Surg 1992;127:1285-1289.
59. Karakousis CP, Emrich LJ, Rao U, Khalil M. Limb salvage in soft tissue sarcomas with selective combination of modalities. Eur J Surg Oncol 1991;17:71-80.
60. Pisters PW, O'Sullivan B, Maki RG. Evidence-based recommendations for local therapy for soft tissue sarcomas. J Clin Oncol 2007;25:1003-1008.
61. Pisters PW, Pollock RE, Lewis VO, et al. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg 2007;246:675-681; discussion 681-682.
62. Kraybill WG, Harris J, Spiro IJ, et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group trial 9514. J Clin Oncol 2006;24:619-625.
63. Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 2004;15:1667-1672. (Pubitemid 39562608)
64. DeLaney TF SI, Suit HD, Gebhardt MC, et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003;56:1117-1127.
65. Pisters PW, Patel SR, Varma DG, et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol 1997;15:3481-3487.
66. Pisters PW, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. Ann Surg Oncol 2002;9:535-542. (Pubitemid 34774413)
67. Maki RG. Role of chemotherapy in patients with soft tissue sarcomas. Expert Rev Anticancer Ther 2004;4:229-236. (Pubitemid 38477337)
68. Tierney JF, Mosseri V, Stewart LA, et al. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 1995;72:469-475.
69. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997;350:1647-1654.
70. Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994;12:1137-1149.
71. Cormier JN, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 2004;22:4567-4574.
72. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003;65:80-84. (Pubitemid 37346738)
73. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001;19:1238-1247.
74. Woll PJ, van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 10008.
75. Alektiar KM, Leung D, Zelefsky MJ, Brennan MF. Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity. J Clin Oncol 2002;20:1643-1650. (Pubitemid 34260546)
76. Antman K, Crowley J, Balcerzak S, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993;11:1276-1285.
77. Antman KH, Judson EA. Dana-Farber Cancer Institute studies in advanced sarcoma. Semin Oncol 1990;1:7-15. (Pubitemid 20060000)
78. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003;CD003293.
79. Edmonson J, Ryan L, Blum R, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993;11:1269-1275.
80. Elias A, Ryan L, Sulkes A, et al. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208-1216. (Pubitemid 19220122)
81. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25:3144-3150.
82. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first- line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-1545.
83. Zalupski M, Metch B, Balcerzak S, et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst 1991;83:926-932.
84. Siehl JM, Thiel E, Schmittel A, et al. Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: a two cohort phase II study [abstract]. J Clin Oncol 2006;24(Suppl 1):Abstract 9563.
85. Siehl JM, Thiel E, Schmittel A, et al. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. Cancer 2005;104:611-617.
86. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002;20:2824-2831.
87. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25:2755-2763.
88. Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22:1706-1712.
89. Bay JO Ray-Coquard I, Fayette J, et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer 2006;119:706-711.
90. Dileo P, Morgan JA, Zahrieh D, et al. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer 2007;109:1863-1869.
91. Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer 2005;104:1706-1712.
92. Talbot SM, Keohan ML, Hesdorffer M, et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer 2003;98:1942-1946.
93. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol 2005;23:576-584.
94. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-1490.
95. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23:5484-5492.
96. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-899.
97. Laverdiere C, Kolb EA, Supko JG, et al. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 2003;98:832-840.
98. Issels RD, Lindner LH, Wust P, et al. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: a phase III randomised pros [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 10009.
99. Issels R, Schlemmer M. Current trials and new aspects in soft tissue sarcoma of adults. Cancer Chemother Pharmacol 2002;49(Suppl 1):S4-8.
100. Grunhagen DJ, Brunstein F, ten Hagen TL, et al. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res 2004;120:65-79.
101. Grunhagen DJ, de Wilt JH, Graveland WJ, et al. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer 2006;106:1776-1784.
102. Whooley BP, Mooney MM, Gibbs JF, Kraybill WG. Effective follow-up strategies in soft tissue sarcoma. Semin Surg Oncol 1999;17:83-87.
103. Whooley BP, Gibbs JF, Mooney MM, et al. Primary extremity sarcoma: what is the appropriate follow-up? Ann Surg Oncol 2000;7:9-14.
104. Kane III JM. Surveillance strategies for patients following surgical resection of soft tissue sarcomas. Curr Opin Oncol 2004;16:328-332.
105. Lewis JJ, Leung D, Casper ES, et al. Multifactorial analysis of long-term follow-up (more man 5 years) of primary extremity sarcoma. Arch Surg 1999;134:190-194.
106. Fleming JB, Cantor SB, Varma DG, et al. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer 2001;92:863-868.
107. Singer S, Antman K, Corson JM, Eberlein TJ. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg 1992;127:548-553; discussion 553-544.
108. References 108-127 are cited in the section on "Retroperitoneal/ Intra-Abdominal Soft Tissue Sarcomas," and are available in the version of these guidelines online at www.NCCN.org.
109. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580. (Pubitemid 28067289)
110. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-710.
111. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-667.
112. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83. (Pubitemid 44692418)
113. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-1478.
114. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
115. Blanke CD, Demetri GD, von Mehren M, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620-625.
116. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134.
117. Blanke CD, Rankin C, Demetri GD, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-632.
118. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-3038.
119. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology 2008;53:245-266.
120. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
121. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004;40:689-695.
122. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-5367.
123. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005;41:1751-1757.
124. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-1103.
125. Gastrointestinal stromal tumor meta-analysis group comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 Patients. J Clin Oncol 2010;28:1247-1253.
126. Eisenberg BL, Harris J, Blanke CD, et al. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009;99:42-47.
127. McAuliffe JC, Hunt KK, Lazar AJ, et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009;16:910-919.
128. Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004;11:465-475.
129. Gold JS, Dematteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg 2006;244:176-184.
130. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
131. Dematteo RP, Antonescu CR, Chadaram V, et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. J Clin Oncol 2005;23(Suppl 1):Abstract 9009.
132. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-1104.
133. Guilhot F. Indications for imatinib mesylate therapy and clinical management. Oncologist 2004;9:271-281.
134. Trent JC, Patel SS, Zhang J, et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer 2010;116:184-192.
135. Benjamin RS, Debiec-Rychter M, Le Cesne A, et al. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. Semin Oncol 2009;36:302-311.
136. Maleddu A, Pantaleo MA, Nannini M, et al. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (review). Oncol Rep 2009;21:1359-1366.
137. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 2006;24:1195-1203.
138. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338.
139. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009;45:1959-1968.
140. Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer 2009;7:11-19.
141. Zhu X, Stergiopoulos K, Wu S. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 2009;48:9-17.
142. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007;370:2011-2019.
143. Torino F, Corsello SM, Longo R, et al. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol 2009;6:219-228.
144. Sepe PS, Moparty B, Pitman MB, et al. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest Endosc 2009;70:254-261.
145. Van den Abbeele AD. The lessons of GIST - PET and PET/CT: a new paradigm for imaging. Oncologist 2008;13(Suppl 2):8-13.
146. Van Den Abbeele AD, Badawi RD, Manola J, et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning [abstract]. J Clin Oncol 2004;22(Suppl 1):Abstract 3012.
147. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007;25:1107-1113.
148. Dematteo RP, Gold JS, Saran L, et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008;112:608-615.
149. Gold JS, Gonen M, Gutierrez A, et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009;10:1045-1052.
150. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24:2325-2331.
151. Wiebe L, Kasza KE, Maki RG, et al. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 10502.
152. Blay JY, Casali PG, Reichardt P, et al. A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): study update [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 10553.
153. Demetri GD, Lo Russo P, MacPherson IR, et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009;15:6232-6240.
154. Fumagalli E, Coco P, Morosi C, et al. Rechallenge with imatinib in GIST patients resistant to second or third line therapy. Presented at the 2009 Connective Tissue Oncology Society 15th Annual Meeting; November 5-7, 2009; Miami Beach, Florida. Abstract 39404.